Control of API release with matrix polymorphism in tristearin microspheres.

Glycerides are widely employed as solid matrices in a range of pharmaceutical intermediates and dosage forms. Diffusion-based mechanisms are responsible for drug release, with both chemical and crystal polymorph differences in the solid lipid matrix cited as controlling factors in drug release rates. This work uses model formulations composed of crystalline caffeine embedded in tristearin to study the impacts to drug release from the two primary polymorphic states of tristearin and dependencies on the conversion routes between them. Using contact angles and NMR diffusometry, this work finds that drug release from the meta-stable α-polymorph is rate limited by a diffusive mechanism relating to its porosity and tortuosity, but initial burst release occurs due to ease of initial wetting. Poor wettability resulting from surface blooming can be rate limiting for the ß-polymorph, resulting in slower initial drug release relative to the α-polymorph. The route to achieve the ß-polymorph strongly impacts the bulk release profile due to differences in crystallite size and packing efficiency. API loading enhances the effective porosity, leading to enhanced drug release at high loadings. These findings offer generalizable principles to guide formulators on the types of impacts to drug release rates that one may expect due to triglyceride polymorphism.

Inhaled PYY(3-36) dry-powder formulation for appetite suppression.

OBJECTIVE: Peptide YY3-36 [PYY(3-36)] has shown efficacy in appetite suppression when dosed by injection modalities (intraperitoneal (IP)/subcutaneous). Transitioning to needle-free delivery, towards inhalation, often utilizes systemic pharmacokinetics as a key endpoint to compare different delivery methods and doses. Systemic pharmacokinetics were evaluated for PYY3-36 when delivered by IP, subcutaneous, and inhalation, the systemic pharmacokinetics were then used to select doses in an appetite suppression pharmacodynamic study. METHODS: Dry-powder formulations were manufactured by spray drying and delivered to mice via nose only inhalation. The systemic plasma, lung tissue, and bronchoalveolar lavage fluid pharmacokinetics of different inhalation doses of PYY(3-36) were compared to IP and subcutaneous efficacious doses. Based on these pharmacokinetic data, inhalation doses of 70:30 PYY(3-36):Dextran T10 were evaluated in a mouse model of appetite suppression and compared to IP and subcutaneous data. RESULTS: Inhalation pharmacokinetic studies showed that plasma exposure was similar for a 2 × higher inhalation dose when compared to subcutaneous and IP delivery. Inhalation doses of 0.22 and 0.65 mg/kg were for efficacy studies. The results showed a dose-dependent (not dose proportional) decrease in food consumption over 4 h, which is similar to IP and subcutaneous delivery routes. CONCLUSIONS: The pharmacokinetic and pharmacodynamics results substantiate the ability of pharmacokinetic data to inform pharmacodynamics dose selection for inhalation delivery of the peptide PYY(3-36). Additionally, engineered PYY(3-36):Dextran T10 particles delivered to the respiratory tract show promise as a non-invasive therapeutic for appetite suppression.

Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10.

Inhaled peptides and proteins have promise for respiratory and systemic disease treatment. Engineered spray-dried powder formulations have been shown to stabilize peptides and proteins and optimize aerosol properties for pulmonary delivery. The current study was undertaken to investigate the in vitro and in vivo inhalation performance of a model spray-dried powder of insulin and dextran 10 in comparison to Exubera™. Dextrans are a class of glucans that are generally recognized as safe with optimum glass transition temperatures well suited for spray drying. A 70% insulin particle loading was prepared by formulating with 30% (w/v) dextran 10. Physical characterization revealed a "raisin like" particle. Both formulations were generated to produce a similar bimodal particle size distribution of less than 3.5 µm MMAD. Four female Beagle dogs were exposed to each powder in a crossover design. Similar presented and inhaled doses were achieved with each powder. Euglycemia was achieved in each dog prior and subsequent to dosing and blood samples were drawn out to 245 min post-exposure. Pharmacokinetic analyses of post-dose insulin levels were similar for both powders. Respective dextran 10-insulin and Exubera exposures were similar producing near identical area under the curve (AUC), 7,728 ± 1,516 and 6,237 ± 2,621; concentration maximums (C max), 126 and 121 (µU/mL), and concentration-time maximums, 20 and 14 min, respectively. These results suggest that dextran-10 and other dextrans may provide a novel path for formulating peptides and proteins for pulmonary delivery.

Coordination chemistry of H2 and N2 in aqueous solution. Reactivity and mechanistic studies using trans-FeII(P2)2X2)-type complexes (P2 = a chelating, water-solubilizing phosphine).

The reactions of the trans-Fe(DMeOPrPE)2Cl2 complex (I; DMeOPrPE = 1,2-bis(bis(methoxypropyl)phosphino)ethane) and its derivatives were studied in aqueous and nonaqueous solvents with a particular emphasis on the binding and activation of H2 and N2. The results show there are distinct differences in the reaction pathways between aqueous and nonaqueous solvents. In water, I immediately reacts to form trans-Fe(DMeOPrPE)2(H2O)Cl+. Subsequent reaction with H2 or N2 yields trans-Fe(DMeOPrPE)2(X2)Cl+ (X2=H2 or N2). In the case of H2, further reactivity occurs to ultimately give the trans-Fe(DMeOPrPE)2(H2)H+ product (III). The pathway for the reaction I --> III was spectroscopically examined: following the initial loss of chloride and replacement with H2, heterolysis of the H2 ligand occurs to form Fe(DMeOPrPE)2(H)Cl; substitution of the remaining chloride ligand by another H2 molecule then occurs to produce trans-Fe(DMeOPrPE)2(H2)H+. In the absence of H2 or N2, trans-Fe(DMeOPrPE)2(H2O)Cl+ slowly reacts in water to form Fe(DMeOPrPE)32+, II. Experiments showed that this species forms by reaction of free DMeOPrPE ligand with trans-Fe(DMeOPrPE)2(H2O)Cl+, where the free DMeOPrPE ligand comes from dissociation from the trans-Fe(DMeOPrPE)2(H2O)Cl+ complex. In nonaqueous solvents, the chloride ligand in I is not labile, and a reaction with H2 only occurs if a chloride abstracting reagent is present. Complex III is a useful synthon for the formation of other water-soluble metal hydrides. For example, the trans-[Fe(DMeOPrPE)2H(N2)]+ complex was generated in H2O by substitution of N2 for the H2 ligand in III. The trans-Fe(DHBuPE)2HCl complex (DHBuPE = 1,2-bis(bis(hydroxybutyl)phosphino)ethane, another water-solubilizing phosphine) was shown to be a viable absorbent for the separation of N2 from CH4 in a pressure swing scheme. X-ray crystallographic analysis of II is the first crystal structure report of a homoleptic tris chelate of FeII containing bidentate phosphine ligands. The structure reveals severe steric crowding at the Fe center.

Precursors to water-soluble dinitrogen carriers. Synthesis of water-soluble complexes of iron(II) containing water-soluble chelating phosphine ligands of the type 1,2-bis(bis(hydroxyalkyl)phosphino)ethane.

The reactions of the water-soluble chelating phosphines 1,2-bis(bis(hydroxyalkyl)phosphino)ethane (alkyl = n-propyl, DHPrPE; n-butyl, DHBuPE; n-pentyl, DHPePE) with FeCl(2).4H(2)O and FeSO(4).7H(2)O were studied as routes to water-soluble complexes that will bind small molecules, dinitrogen in particular. The products that form and their stereochemistry depend on the solvent, the counteranion, and the alkyl chain length on the phosphine. In alcoholic solvents, the reaction of FeCl(2).4H(2)O with 2 equiv of DHBuPE or DHPePE gave trans-Fe(L(2))(2)Cl(2). The analogous reactions in water with DHBuPE and DHPePE gave only cis products, and the reaction of FeSO(4).7H(2)O with any of the phosphines gave only cis-Fe(L(2))(2)SO(4). These results are interpreted as follows. The trans stereochemistry of the products from the reactions of FeCl(2).4H(2)O in alcohols is suggested to be the consequence of the trans geometry of the Fe(H(2)O)(4)Cl(2) complex, i.e., substitution of the water molecules by the phosphines retains the geometry of the starting material. The formation of cis-Fe(DHPrPE)(2)Cl(2) is an exception to this result because the coordination of two -OH groups forms two six-membered rings, as shown in the X-ray structure of the molecule. DHBuPE and DHPePE reacted with FeSO(4).7H(2)O in water to initially yield cis-Fe(P(2))(2)SO(4) compounds, but subsequent substitution reactions occurred over several hours to give sequentially trans-Fe(DHBuPE)(2)(H(2)O)(SO(4)) and then trans-[Fe(DHBuPE)(2)(H(2)O)(2)]SO(4). The rate constants and activation reactions for these aquation reactions were determined and are consistent with dissociatively activated mechanisms. The cis- and trans-Fe(L(2))(2)X (X = (Cl)(2) or SO(4)) complexes react with N(2), CO, and CH(3)CN to yield trans complexes with bound N(2), CO, or CH(3)CN. The crystal structures of the cis-Fe(DHPrPE)(2)SO(4), trans-Fe(DHPrPE)(2)(CO)SO(4), trans-Fe(DHBuPE)(2)Cl(2), trans-[Fe(DHBuPE)(2)(CO)(Cl)][B(C(6)H(5))(4)], trans-Fe(DMeOPrPE)(2)Cl(2), trans-Fe(DMeOPrPE)(2)Br(2), and trans-[Fe(DHBuPE)(2)Cl(2)]Cl complexes are reported. As expected from using water-soluble phosphines, the complexes reported herein are water soluble (generally greater than 0.5 M at 23 degrees C).

Synthesis and Characterization of Water-Soluble 1,2-Bis(bis(hydroxyalkyl)phosphino)ethane Ligands and Their Nickel(II), Ruthenium(III), and Rhodium(I) Complexes.

The syntheses of the water-soluble, chelating phosphines 1,2-bis(bis(hydroxybutyl)phosphino)ethane (1, n = 3; DHBuPE) and 1,2-bis(bis(hydroxypentyl)phosphino)ethane (1, n = 4; DHPePE) are reported. These ligands (and, in general, other 1,2-bis(bis(hydroxyalkyl)phosphino)ethane ligands) can be used to impart water solubility to metal complexes. As examples of this, the [Ni(DHPrPE)(2)Cl]Cl (2), [Rh(DHPrPE)(2)][Cl] (3), and [Ru(DHBuPE)(2)Cl(2)][Cl] (4) complexes were synthesized; they are indeed soluble in water (>0.5 M). Crystals of DHPrPE (1, n = 2) are monoclinic, space group P2(1)/c, with a = 9.5935(8) Å, b = 9.353(2) Å, c = 10.655(2) Å, alpha = 90 degrees, beta = 100.03(1) degrees, gamma = 90, V = 941.5(5) Å(3), R = 0.051, and Z = 2. Crystals of [Ni(DHPrPE)(2)Cl]Cl (2) are monoclinic, space group I2, with a = 15.951(3) Å, b = 11.454(2) Å, c = 20.843(3) Å, alpha = 90 degrees, beta = 91.24(2) degrees, gamma = 90 degrees, V = 3807(2) Å(3), R = 0.062, and Z = 4. Crystals of [Rh(DHPrPE)(2)][Cl] (3) are triclinic, space group P&onemacr;, with a = 13.900(2) Å, b = 15.378(2) Å, c = 18.058(2) Å, alpha = 87.71(1) degrees, beta = 75.03(1) degrees, gamma = 85.24(1), V = 3715(2) Å(3), R = 0.044, and Z = 4. Crystals of [Ru(DHBuPE)(2)Cl(2)][Cl] (4) are monoclinic, space group C2/c, with a = 14.310(2) Å, b = 21.630(2) Å, c = 15.459(3) Å, alpha = 90 degrees, beta = 99.83(1) degrees, gamma = 90, V = 4715(1) Å(3), R = 0.056, and Z = 4.